TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02115295: Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 508 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT02115295 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02115295 Rescue Dossier →